Company Encyclopedia
View More
name
Envista
NVST.US
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products.
1.407 T
NVST.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking54/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE0.50%D
    • Profit Margin0.58%C
    • Gross Margin55.99%B
  • Growth ScoreC
    • Revenue YoY4.73%C
    • Net Profit YoY101.14%A
    • Total Assets YoY2.39%C
    • Net Assets YoY0.51%C
  • Cash ScoreB
    • Cash Flow Margin17135.95%A
    • OCF YoY4.73%C
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreC
    • Gearing Ratio45.27%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Envista Holdings Corporation to Participate in Evercore Healthcare Conference

    Envista Holdings Corporation will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025, featuring a fireside chat. A live audio webcast and replay will be available on Envista's website. The news was generated by Public Technologies using AI and is for informational purposes only, not financial advice. Original content was published via PR Newswire on November 25, 2025.

    Reuters·
    US
    NVST
    -1.56%
    Reuters·
    US
    NVST
    -1.56%

    Envista Holdings’ Earnings Call Highlights Strong Growth

    Envista Holdings' earnings call revealed strong financial performance, with a Q3 core growth of 9% and an adjusted EPS of $0.32. The company raised its full-year 2025 guidance, expecting core revenue growth of about 4%. Key highlights included the shipment of the 1 millionth Spark aligner case and market share gains in most segments. Despite challenges from increased tariff costs and uncertainties in the China market, Envista's operational efficiency and R&D investments support its positive outlook for the future.

    Tip Ranks·
    US
    NVST
    -1.56%
    Tip Ranks·
    US
    NVST
    -1.56%

    Envista Holdings: Strong Q3 Performance and Upward Guidance, Yet Valuation Concerns Justify Hold Rating

    David Saxon has assigned a Hold rating to Envista Holdings despite its strong Q3 performance, where the company surpassed revenue and earnings expectations and raised its guidance. The Spark business has become profitable, enhancing operating margins. However, Saxon cites valuation concerns relative to peers in the dental industry as the reason for the neutral recommendation, indicating a cautious outlook on future stock performance.

    Tip Ranks·
    US
    NVST
    -1.56%
    Tip Ranks·
    US
    NVST
    -1.56%

    Envista Holdings: Positive Growth Trends and Margin Improvements Drive Buy Rating

    Envista Holdings has received a Buy rating from Allen Lutz, driven by positive core growth trends and expected margin improvements. The company is projected to finish 2025 stronger, aided by Spark's profitability shift and implant growth in North America. Despite market challenges, Envista's strategic reinvestments have shown potential for upside. While the VBP 2.0 cycle in China may pose a headwind, manageable impacts are anticipated. Margins are improving, with expectations of further enhancement by 2026, supported by a price objective of $25. TR | OpenAI – 4o also upgraded the stock to a Buy with a $22 target.

    Tip Ranks·
    US
    NVST
    -1.56%
    Tip Ranks·
    US
    NVST
    -1.56%

    Envista Holdings Reports Strong Q3 2025 Results

    Envista Holdings Corporation reported strong Q3 2025 results, with core sales of $670 million, a 9.4% increase from Q3 2024. Adjusted EBITDA rose 77% to $97 million, and adjusted EPS increased 167% to $0.32. Despite a GAAP net loss of $30 million, the company maintained strong cash flow and continued its share repurchase program. Year-to-date sales reached $1,969 million, with a 5% core sales growth. Envista updated its 2025 guidance, projecting 4% core sales growth and a 14% adjusted EBITDA margin, focusing on innovation and market strength for future growth.

    Tip Ranks·
    US
    NVST
    -1.56%
    Tip Ranks·
    US
    NVST
    -1.56%
    © 2025 Longbridge｜Disclaimer